Skip to main content
HLB SCIENCE Inc. logo

HLB SCIENCE Inc. — Investor Relations & Filings

Ticker · 343090 ISIN · KR7343090007 KO Professional, scientific and technical activities
Open in API
Filings indexed 187 across all filing types
Latest filing 2024-11-28 Regulatory Filings
Country KR South Korea
Listing KO 343090

About HLB SCIENCE Inc.

https://hlbscience.com/eng/index.php

HLB SCIENCE Inc. is a biopharmaceutical company specializing in the development of innovative drugs and diagnostics for infectious and immune-related diseases. The company's primary research focuses on creating therapeutics for sepsis, superbacteria infections, and Alzheimer's disease. Its key pipeline candidate for sepsis, DD-S052P, is a novel antibiotic designed to eliminate both bacteria and their associated endotoxins to mitigate cytokine storms. For Alzheimer's disease, HLB SCIENCE is advancing DD-A279, a treatment that modulates lipopolysaccharides (LPS) and gram-negative bacteria in the central nervous system. This therapeutic effort is complemented by the development of DD-A514, a diagnostic kit for the early detection of Alzheimer's.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최결과
Regulatory Filings Classification · 100% confidence The document is a short, structured announcement reporting the results of an Investor Relations (IR) event held by HLB Science. It provides details such as the date, location (online platform), attendees, and a summary of the topics covered (company status and future plans). It also directs readers to where the actual presentation materials can be found. Since it is an announcement of an event and its outcome rather than the presentation slides themselves, and it fits the regulatory disclosure format for IR activities, it is classified as a Regulatory Filing (RNS).
2024-11-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent filing) used to disclose changes in share ownership by insiders or major shareholders. Based on the provided categories, this fits the definition of 'Director's Dealing' (DIRS), which covers personal share transactions and ownership changes by company directors and major shareholders.
2024-11-12 Korean
전환가액의조정 (제4회차)
Capital/Financing Update Classification · 100% confidence The document is an official notice regarding the adjustment of the conversion price for convertible bonds (4th series) issued by HLB Science. It details the change in conversion price from 2,221 KRW to 1,883 KRW due to a decline in market price, and updates the number of convertible shares. This type of filing relates to capital structure changes and financing instruments, which falls under the 'Capital/Financing Update' category.
2024-11-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including major shareholding notifications and changes in special relationships. This falls under the 'Major Shareholding Notification' category.
2024-10-16 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by HLB Science. It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2024-10-10 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding a decision to issue new shares (capital increase/유상증자). This is a formal regulatory filing detailing the terms of a capital raise, including the number of shares, pricing, and the purpose of the funds. It fits the definition of a 'Share Issue/Capital Change' (SHA) filing as it specifically details the issuance of new shares and the associated capital structure changes.
2024-09-24 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.